BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 12169712)

  • 21. Tropical disease vaccines.
    Riddell A; Pollard AJ
    Expert Rev Vaccines; 2003 Feb; 2(1):105-12. PubMed ID: 12901602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Health systems reform: What can western Europe contribute to Latin America?].
    Infante A; Gozzer E
    Educ Med Salud; 1995; 29(3-4):286-303. PubMed ID: 8850123
    [No Abstract]   [Full Text] [Related]  

  • 23. Health innovation networks to help developing countries address neglected diseases.
    Morel CM; Acharya T; Broun D; Dangi A; Elias C; Ganguly NK; Gardner CA; Gupta RK; Haycock J; Heher AD; Hotez PJ; Kettler HE; Keusch GT; Krattiger AF; Kreutz FT; Lall S; Lee K; Mahoney R; Martinez-Palomo A; Mashelkar RA; Matlin SA; Mzimba M; Oehler J; Ridley RG; Senanayake P; Singer P; Yun M
    Science; 2005 Jul; 309(5733):401-4. PubMed ID: 16020723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 25. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM; Tebbens RJ
    Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wyeth responds to criticism.
    Stiles GM
    Md Med; 2005; 6(4):5, 7-8; author reply 8. PubMed ID: 16454430
    [No Abstract]   [Full Text] [Related]  

  • 28. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 29. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community.
    Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ
    J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No money, no meds.
    Mabry M
    Newsweek; 1999 Jul; 134(2):32-3. PubMed ID: 10538648
    [No Abstract]   [Full Text] [Related]  

  • 33. Public Law 100-202, Joint Resolution making further continuing appropriations for the fiscal year 1988, and for other purposes, 22 December 1987.
    United States
    Annu Rev Popul Law; 1988; 15():215. PubMed ID: 12289429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investors, HMOs, policy makers see value in vaccines.
    Fox JL
    Nat Biotechnol; 1996 Dec; 14(13):1646-7. PubMed ID: 9634838
    [No Abstract]   [Full Text] [Related]  

  • 36. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug industry in India is threatened by free trade agreement].
    Jeppsson A
    Lakartidningen; 2009 Oct 7-13; 106(41):2589. PubMed ID: 19927922
    [No Abstract]   [Full Text] [Related]  

  • 40. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.